Efficacy of lifestyle interventions in physical health management of patients with severe mental illness

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Chacón, Fernando ^a   Mora, Fernando ^b   Gervás Ríos, Alicia ^a   Gilaberte, Inmaculada ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; DIET; DISEASE SEVERITY; DRUG ABUSE; EATING HABIT; EXERCISE; GENETIC PREDISPOSITION; HEALTH CARE ACCESS; HUMAN; LIFESTYLE MODIFICATION; MENTAL DISEASE; OBESITY; PHYSICAL CAPACITY; REVIEW; SEDENTARY LIFESTYLE; SMOKING;

EID: 80052848447     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-22     Document Type: Review

References (101)

1. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, Lieberman JA. Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008, 69:514-519. 10.4088/JCP.v69n0401, 18370570.
2. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009, 66:713-720. 10.1001/archgenpsychiatry.2009.61, 19581562.
3. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116:317-333. 10.1111/j.1600-0447.2007.01095.x, 17919153.
4. Surtees PG, Wainwright NW, Luben RN, Wareham NJ, Bingham SA, Khaw KT. Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study. Am J Psychiatry 2008, 165:515-523. 10.1176/appi.ajp.2007.07061018, 18245176.
5. Piatt EE, Munetz MR, Ritter C. An examination of premature mortality among decedents with serious mental illness and those in the general population. Psychiatr Serv 2010, 61:663-668. 10.1176/appi.ps.61.7.663, 20592000.
6. Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 2002, 53:861-867. 10.1176/appi.ps.53.7.861, 12096170.
7. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009, 3:5-15. 10.1016/j.pcd.2008.10.005, 19083283.
8. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 2005, 20(Suppl 4):S335-S339.
9. Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol 2005, 19(Suppl):47-55. 10.1177/0269881105058380, 16280337.
10. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ 2001, 322:443-444. 10.1136/bmj.322.7284.443, 1119672, 11222406.
11. Maj M. Necesidad de proteger y fomentar la salud física en personas con enfermedad mental grave. Rev Psiquiatr Salud Ment (Barc) 2009, 2:1-4.
12. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 2007, 164:402-408. 10.1176/appi.ajp.164.3.402, 17329463.
13. Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry 2006, 67:e08. 10.4088/JCP.0906e08, 17081075.
14. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005, 66:183-194. 10.4088/JCP.v66n0205, 15705003.
15. Marwaha S, Johnson S, Bebbington P, Angermeyer MC, Brugha T, Azorin JM, Kilian R, Kornfeld A, Toumi M, . EuroSC Study Group Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. J Nerv Ment Dis 2008, 196:87-94. 10.1097/NMD.0b013e318162aa9c, 18277215, EuroSC Study Group.
16. Sáiz Ruiz J, Bobes García J, Vallejo Ruiloba J, Giner Ubago J, García-Portilla González MP, . Grupo de Trabajo sobre la Salud Física del Paciente con Esquizofrenia Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry [in Spanish]. Actas Esp Psiquiatr 2008, 36:251-264. Grupo de Trabajo sobre la Salud Física del Paciente con Esquizofrenia.
17. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007, 21:911-936. 10.2165/00023210-200721110-00004, 17927296.
18. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233. 10.1016/j.schres.2010.07.012, 20692814.
19. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, . EUFEST study group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097. 10.1016/S0140-6736(08)60486-9, 18374841, EUFEST study group.
20. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res 2008, 99:13-22. 10.1016/j.schres.2007.10.022, 18053689.
21. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res 2009, 107:115-121. 10.1016/j.schres.2008.09.028, 18993033.
22. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007, 68:1733-1740. 10.4088/JCP.v68n1113, 18052567.
23. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bul 2002, 28:5-16.
24. American Psychiatric Association Practice Guideline for Schizophrenia 2004, Arlington, VA: American Psychiatric Association, American Psychiatric Association.
25. Bobes J, Ruiz JS, Montes JM, Mostaza J, Rico-Villademoros F, Vieta E. Consenso Español de Salud Física del Paciente con Trastorno Bipolar. Rev Psiquiatr Salud Ment 2008, 1:26-37.
26. Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, Kirkpatrick B. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull 2009, 35:437-442. 10.1093/schbul/sbn169, 2659310, 19279086.
27. Fernandez-Egea E, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis. Mol Psychiatry 2009, 14:989-991. 10.1038/mp.2009.45, 19851279.
28. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424. 10.1016/j.eurpsy.2009.01.005, 19682863.
29. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs 2009, 23:583-602. 10.2165/00023210-200923070-00004, 19552486.
30. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand 2009, 119:171-179. 10.1111/j.1600-0447.2008.01334.x, 19178394.
31. Auquier P, Lançon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2006, 15:873-879. 10.1002/pds.1325, 17058327.
32. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005, 150:1115-1121. 10.1016/j.ahj.2005.02.007, 16338246.
33. De Hert M, Peuskens J, van Winkel R. Mortality in patients with schizophrenia. Lancet 2009, 374:1591.
34. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009, 66:1253-1262. 10.1001/archgenpsychiatry.2009.142, 2933113, 19884613.
35. Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc 2009, 49(Suppl 1):S3-S9.
36. Germino FW. The management and treatment of hypertension. Clin Cornerstone 2009, 9(Suppl 3):S27-S33.
37. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007, 92:1581-1589. 10.1210/jc.2007-0275, 17483372.
38. Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev 2006, 27:779-793.
39. Citrome L, Jaffe A, Levine J, Martello D. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr Serv 2006, 57:1132-1139. 10.1176/appi.ps.57.8.1132, 16870964.
40. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006, 8:125-135. 10.1111/j.1463-1326.2005.00495.x, 16448516.
41. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 2008, 7:761-769. 10.1517/14740330802423234, 18983222.
42. von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl 2009, 438:15-21.
43. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002, 70:19-26. 10.1016/S0165-0327(01)00456-6, 12113916.
44. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004, 21:515-523. 10.1111/j.1464-5491.2004.01199.x, 15154933.
45. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005, 17:83-93. 10.1080/10401230590932380, 16075661.
46. Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord 2006, 95:13-17. 10.1016/j.jad.2006.03.027, 16777235.
47. Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 2008, 8:84. 10.1186/1471-244X-8-84, 2570660, 18817565.
48. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349. 10.1176/appi.ajp.161.8.1334, 15285957.
49. Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C, . RICAVA Study Group Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009, 24:431-441. 10.1016/j.eurpsy.2009.07.010, 19783126, RICAVA Study Group.
50. Aranceta J, Moreno B, Moya M, Anadón A. Prevention of overweight and obesity from a public health perspective. Nutr Rev 2009, 67(Suppl 1):S83-S8.
51. Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis 2003, 191:799-805. 10.1097/01.nmd.0000100923.20188.2d, 14671456.
52. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006, 18:23-31.
53. Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol 2007, 27:46-51. 10.1097/JCP.0b013e31802e5126, 17224711.
54. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008, 193:101-107. 10.1192/bjp.bp.107.042853, 18669990.
55. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009, 10:527-542. 10.1111/j.1467-789X.2009.00589.x, 19460111.
56. Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008, 22:477-495. 10.2165/00023210-200822060-00003, 18484791.
57. Brown WV, Fujioka K, Wilson PW, Woodworth KA. Obesity: why be concerned?. Am J Med 2009, 122(Suppl 1):S4-S11.
58. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88. 10.1186/1471-2458-9-88, 2667420, 19320986.
59. Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010, 117:75-82. 10.1016/j.schres.2009.12.016, 20080392.
60. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009, 119:4-14. 10.1111/j.1600-0447.2008.01317.x, 19133915.
61. Lin CC, Liu CS, Li CI, Lin WY, Lai MM, Lin T, Chang PC, Lee YD, Chen CC, Lin CH, Yang CW, Hsiao CY, Chen W, Li TC. The relation of metabolic syndrome according to five definitions to cardiovascular risk factors - a population-based study. BMC Public Health 2009, 9:484. 10.1186/1471-2458-9-484, 2805641, 20028565.
62. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, , . International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity.
63. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008, 93(Suppl 1):S9-S30.
64. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009, 70(Suppl 3):22-29. 10.4088/JCP.7075su1c.04, 19570498.
65. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007, 13(Suppl):S170-S177.
66. Fagerström K, Aubin HJ. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin 2009, 25:511-518. 10.1185/03007990802707568, 19192999.
67. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009, 104:719-733. 10.1111/j.1360-0443.2009.02545.x, 19413788.
68. Fleming P, Godwin M. Lifestyle interventions in primary care: systematic review of randomized controlled trials. Can Fam Physician 2008, 54:1706-1713. 2602636, 19074715.
69. Demark-Wahnefried W, Jones LW. Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am 2008, 22:319-342. 10.1016/j.hoc.2008.01.012, 2383876, 18395153.
70. Brown T, Avenell A, Edmunds LD, Moore H, Whittaker V, Avery L, Summerbell C. Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults. Obes Rev 2009, 10:627-638. 10.1111/j.1467-789X.2009.00641.x, 19754634.
71. Madden SG, Loeb SJ, Smith CA. An integrative literature review of lifestyle interventions for the prevention of type II diabetes mellitus. J Clin Nurs 2008, 17:2243-2256. 10.1111/j.1365-2702.2008.02335.x, 18705701.
72. Grundy SM. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. Am J Med 2007, 120(Suppl 1):S3-8.
73. Vadstrup ES, Frølich A, Perrild H, Borg E, Røder M. Lifestyle intervention for type 2 diabetes patients: trial protocol of The Copenhagen Type 2 Diabetes Rehabilitation Project. BMC Public Health 2009, 9:166. 10.1186/1471-2458-9-166, 2694179, 19480671.
74. Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009, 29:223-256. 10.1146/annurev-nutr-080508-141200, 19400751.
75. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991, 34:891-898. 10.1007/BF00400196, 1778354.
76. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, . Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. 10.1056/NEJM200105033441801, 11333990, Finnish Diabetes Prevention Study Group.
77. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008, 299:185-193. 10.1001/jama.2007.56-b, 18182600.
78. Tuomilehto J. Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes. Diabetes Care 2009, 32(Suppl 2):S189-S193. 2811487, 19875550.
79. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation 2009, 119:2026-2031. 10.1161/CIRCULATIONAHA.108.809491, 2995494, 19349322.
80. Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension 2009, 54:756-762. 10.1161/HYPERTENSIONAHA.109.135178, 19704106.
81. Smith S, Yeomans D, Bushe CJ, Eriksson C, Harrison T, Holmes R, Mynors-Wallis L, Oatway H, Sullivan G. A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. Eur Psychiatry 2007, 22:413-418. 10.1016/j.eurpsy.2007.07.002, 17765483.
82. Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005, 20:447-448. 10.1002/hup.707, 16106486.
83. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003, 54:1155-1157. 10.1176/appi.ps.54.8.1155, 12883145.
84. Poole Hoffmann V, Bushe C, Meyers AL, Greenwood T, Benzing L, Ahl J. A wellness intervention program for patients with mental illness: self-reported outcomes. Prim Care Companion J Clin Psychiatry 2008, 10:329-331. 10.4088/PCC.v10n0411c, 2528241, 18787679.
85. Hoffmann VP, Ahl J, Meyers A, Schuh L, Shults KS, Collins DM, Jensen L. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry 2005, 66:1576-1579. 10.4088/JCP.v66n1213, 16401160.
86. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003, 35:237-241. 10.1111/j.1547-5069.2003.00237.x, 14562491.
87. Bushe CJ, McNamara D, Haley C, McCrossan MF, Devitt P. Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. BMC Psychiatry 2008, 8:76. 10.1186/1471-244X-8-76, 2551599, 18793390.
88. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry 2006, 67:547-553. 10.4088/JCP.v67n0405, 16669719.
89. Lee SJ, Choi EJ, Kwon JS. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2008, 69:555-562. 10.4088/JCP.v69n0406, 18312061.
90. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007, 115:286-294. 10.1111/j.1600-0447.2006.00906.x, 17355519.
91. Holt RI, Pendlebury J, Wildgust HJ, Bushe CJ. Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J Clin Psychiatry 2010, 71:800-805. 10.4088/JCP.09m05627gre, 20361917.
92. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry 2007, 41:980-989. 10.1080/00048670701689428, 17999270.
93. Bushe C, Haddad P, Peveler R, Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005, 19(Suppl):28-35. 10.1177/0269881105058682, 16280335.
94. McKibbin CL, Patterson TL, Norman G, Patrick K, Jin H, Roesch S, Mudaliar S, Barrio C, O'Hanlon K, Griver K, Sirkin A, Jeste DV. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res 2006, 86:36-44. Epub 2006 Jul 12, 10.1016/j.schres.2006.05.010, 16842977.
95. Camhi SM, Stefanick ML, Katzmarzyk PT, Young DR. Metabolic syndrome and changes in body fat from a low-fat diet and/or exercise randomized controlled trial. Obesity (Silver Spring) 2010, 18:548-554.
96. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K. Preventing weight gain: one-year results of a randomized lifestyle intervention. Am J Prev Med 2009, 37:270-277. 10.1016/j.amepre.2009.06.011, 19765497.
97. Weinberger AH, Hitsman B, Papandonatos GD, Sacco KA, Vessicchio JC, George TP. Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation. J Clin Psychopharmacol 2009, 29:601-603. 10.1097/JCP.0b013e3181bfd0b4, 19910728.
98. Bradshaw T, Lovell K, Harris N. Healthy living interventions and schizophrenia: a systematic review. J Adv Nurs 2005, 49:634-654. 10.1111/j.1365-2648.2004.03338.x, 15737224.
99. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000, 157:1835-1842. 10.1176/appi.ajp.157.11.1835, 11058482.
100. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv 2002, 53:1166-1170. 10.1176/appi.ps.53.9.1166, 12221317.
101. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 2008, 168:1950-1960. 10.1001/archinte.168.18.1950, 18852395.